Toxicology – Carisoprodol

Core concept

Carisoprodol is a centrally acting sedative muscle relaxant that is metabolized to the longer-acting sedative-hypnotic meprobamate.

The characteristic overdose syndrome is:

CNS depression + ataxia → respiratory depression/coma ± hypotension

However, unlike a simple sedative overdose, carisoprodol can also cause:

• Agitation
• Myoclonus or abnormal movements
• Seizures
• Delirium
• Serotonergic features

Severe poisoning is especially dangerous when combined with:

Opioids + benzodiazepines + alcohol or other CNS depressants

because respiratory-depressant effects are additive. Current labeling documents fatal overdoses both from carisoprodol alone and particularly in multidrug exposures.

The main treatment is:

Airway protection + ventilation + supportive cardiovascular care

There is no established specific antidote.

Current Forms and Uses

Carisoprodol remains available as an oral prescription muscle relaxant.

Current U.S. labeling recommends:

250–350 mg orally three times daily and at bedtime

for the relief of discomfort associated with:

Acute painful musculoskeletal conditions

Treatment should be limited to:

2–3 weeks

because longer-term effectiveness has not been established and dependence/abuse become increasingly important concerns.

Pediatric use

The older text states that the drug is not recommended below age 12.

Current labeling states:

Safety, efficacy, and pharmacokinetics have not been established in patients <16 years.

Controlled Substance / Abuse Potential

In the United States, carisoprodol is a:

Schedule IV controlled substance

and has recognized potential for:

• Abuse
• Misuse
• Dependence
• Diversion
• Withdrawal

This is clinically important because many severe overdoses occur in people also using:

• Opioids
• Benzodiazepines
• Alcohol
• Other sedatives

A 2025 UK government review similarly emphasized increased overdose danger when carisoprodol is combined with opioids or benzodiazepines.

Combination Products

Carisoprodol has historically been marketed in combination preparations containing:

• Aspirin/salicylate
• Aspirin + codeine

Therefore, whenever a commercial combination preparation is involved:

Do not attribute the entire syndrome to carisoprodol.

Specifically consider:

• Salicylate toxicity
• Opioid toxicity

according to the actual ingredients.

Toxic Dose

There is no reliable single toxic dose.

Gram-level ingestion can produce serious toxicity, but severity varies greatly depending on:

• Opioid/sedative tolerance
• Coingestants
• Age
• Renal function
• Hepatic function
• CYP2C19 phenotype
• Chronic carisoprodol exposure

The older concept that “gram quantities intoxicate an adult” remains qualitatively useful, but there is no validated numerical dose that separates mild from severe poisoning.

Therefore:

Clinical findings matter more than the reported dose.

Pathophysiology

Central nervous system effects

The precise therapeutic mechanism is still not completely established.

Current FDA labeling states that carisoprodol:

• Acts centrally
• Does not directly relax skeletal muscle
• Is associated experimentally with altered interneuronal activity in the spinal cord and descending reticular formation.

Modern pharmacologic evidence also supports modulation of:

GABA-A receptor activity

which helps explain its:

• Sedative
• Anxiolytic
• Abuse
• Respiratory-depressant

properties.

Meprobamate – Important Active Metabolite

Carisoprodol undergoes hepatic metabolism through:

CYP2C19

to form:

Meprobamate

Meprobamate has significant:

• Sedative
• Anxiolytic
• CNS-depressant

activity.

This creates a clinically important two-stage toxicology picture:

Carisoprodol exposure → parent-drug effects → conversion to longer-acting meprobamate

Pharmacokinetics

Current labeling gives approximate half-lives of:

Carisoprodol

~2 hours

Meprobamate

~10 hours

Therefore:

Sedation can persist substantially longer than the parent carisoprodol concentration would suggest.

This is especially relevant after:

• Large overdose
• Repeated dosing
• Chronic misuse
• Renal dysfunction

CYP2C19 Pharmacogenetics

CYP2C19 activity varies substantially between individuals.

Poor metabolizers can have approximately:

4-fold greater carisoprodol exposure

with correspondingly reduced conversion to meprobamate.

This may partly explain variation in:

• Clinical effects
• Duration
• Neuroexcitation versus sedation

Drug Interactions

CNS depressants

The most clinically important interaction is:

Carisoprodol + another CNS depressant → additive sedation/respiratory depression

Important agents include:

• Opioids
• Benzodiazepines
• Alcohol
• Tricyclic antidepressants
• Sedating antihistamines
• Other muscle relaxants

CYP2C19 inhibitors

Examples include:

• Omeprazole
• Fluvoxamine

These may:

↑ carisoprodol exposure + ↓ meprobamate formation

CYP2C19 inducers

Examples include:

• Rifampin
• St John’s wort

These may:

↓ carisoprodol exposure + ↑ meprobamate formation

Clinical Features

CNS Depression

The most common overdose manifestation is:

CNS depression

which may progress through:

• Dizziness
• Drowsiness
• Ataxia
• Dysarthria
• Poor coordination
• Stupor
• Coma

Current FDA labeling specifically reports:

• Coma
• Respiratory depression
• Death

after overdose.

Respiratory

Severe toxicity may cause:

Respiratory depression → hypoventilation → hypercapnia/hypoxia → respiratory arrest

Risk increases substantially with:

• Opioids
• Benzodiazepines
• Alcohol

Patients with profound CNS depression may lose airway reflexes and require intubation.

Neuroexcitation / Abnormal Movements

Carisoprodol poisoning is unusual among sedatives because some patients develop marked CNS excitation.

Reported manifestations include:

• Agitation
• Tremor
• Myoclonus
• Rigidity
• Dystonic reactions
• Choreiform or unusual “robot-like” movements
• Hyperreflexia
• Delirium

The clinical pattern can differ from that of pure meprobamate poisoning.

The 2025 UK toxicology review describes parent carisoprodol toxicity as more likely to produce:

• Tachycardia
• Tremor
• Shivering
• Myoclonus/abnormal movements
• Agitation

whereas meprobamate more typically causes:

CNS depression + hypotension + hyporeflexia/flaccidity.

Seizures

Seizures have been reported in overdose.

Current labeling notes that many seizure cases involve:

• Multiple drug overdoses
• Alcohol
• Drugs of abuse

rather than pure isolated therapeutic exposure.

Serotonin Toxicity

Current FDA labeling states that:

Serotonin syndrome has been reported with carisoprodol intoxication.

Possible findings include:

• Agitation
• Tremor
• Hyperreflexia
• Clonus/myoclonus
• Hyperthermia
• Tachycardia

However:

Serotonin toxicity is not the usual presentation of carisoprodol overdose.

It should be particularly considered when there is:

• Marked neuromuscular excitation
• Hyperthermia
• Clonus
• Coexposure to serotonergic drugs

Case-series evidence has described serotonergic features after high-dose intoxication.

Cardiovascular

Possible manifestations include:

• Tachycardia
• Postural hypotension
• Hypotension
• Syncope

Severe poisoning may produce:

• Profound hypotension
• Cardiovascular instability

Current labeling specifically identifies hypotension as a possible serious overdose manifestation.

Gastrointestinal

Possible effects include:

• Nausea
• Vomiting
• Epigastric discomfort

These are generally less clinically important than respiratory/CNS toxicity.

Pupils / Eyes

Reported overdose findings include:

• Nystagmus
• Blurred vision
• Mydriasis

Thus pupil findings are nonspecific and should not be used to distinguish carisoprodol reliably from other sedatives.

Withdrawal

An important feature largely underemphasized in older descriptions is physical dependence.

Abrupt cessation after prolonged/high-dose use may cause:

• Insomnia
• Anxiety
• Vomiting
• Abdominal cramps
• Headache
• Tremor
• Muscle twitching
• Ataxia
• Hallucinations
• Psychosis

The syndrome can resemble withdrawal from other sedative-hypnotics.

Therefore:

Do not abruptly discontinue heavy chronic carisoprodol use without considering withdrawal risk.

Diagnosis

Diagnosis is mainly clinical:

Exposure history + CNS depression or mixed sedative/neuroexcitant toxidrome

There is no rapidly available serum concentration routinely required for treatment.

Differential Diagnosis

Carisoprodol overdose may resemble:

• Ethanol
• Benzodiazepines
• Barbiturates
• Meprobamate
• Other muscle relaxants
• Gabapentinoids
• Opioids
• Sedating antihistamines
• Clonidine

If abnormal movements, hyperreflexia, or agitation predominate, consider:

• Serotonin syndrome
• Stimulant intoxication
• Anticholinergic poisoning
• Withdrawal syndromes

Essential Assessment

Evaluate:

• Airway
• Respiratory rate
• Depth of ventilation
• Mental status
• Blood pressure
• Heart rate
• Temperature
• Bedside glucose

Pulse oximetry should be used, but remember:

Supplemental oxygen can maintain a normal SpO₂ despite significant hypoventilation.

Therefore, in significant CNS depression consider:

• Continuous capnography
• Venous/arterial blood gas

Laboratory Tests

In moderate/severe poisoning consider:

• Electrolytes
• Glucose
• BUN
• Creatinine
• Bicarbonate
• Blood gas
• CK after seizures/prolonged immobilization

Obtain an ECG in:

• Significant overdose
• Syncope
• Hypotension
• Suspected coingestion

For intentional overdose, consider:

• Acetaminophen concentration
• Salicylate concentration

and other testing based on the actual product involved.

Carisoprodol / Meprobamate Levels

Specific quantitative assays exist but are generally:

• Not rapidly available
• Not required for routine clinical management

Management should be guided primarily by:

• Mental status
• Ventilation
• Hemodynamics
• Coingestants

A standard emergency urine drug screen may not reliably identify carisoprodol unless a specific assay is included.

A recent UK review recommended that specialized toxicologic assessment include both carisoprodol and meprobamate because incomplete testing can miss clinically important exposures.

Treatment

1. Airway and Ventilation

The most important treatment is:

Supportive airway management

For significant CNS depression:

• Position airway appropriately
• Provide supplemental oxygen
• Assist ventilation if necessary
• Suction secretions

Intubate for:

• Loss of airway reflexes
• Severe hypoventilation
• Persistent coma
• Recurrent seizures
• Respiratory failure

Current FDA labeling specifically recommends considering tracheal intubation when severe CNS depression compromises airway protection.

Naloxone

Naloxone is not an antidote to carisoprodol.

However, because opioid coingestion is common:

Respiratory depression + possible opioid exposure → give naloxone appropriately

while continuing ventilatory support.

A response to naloxone suggests an opioid contribution but does not exclude simultaneous carisoprodol toxicity.

Gastrointestinal Decontamination

Do Not Induce Vomiting

Do not induce emesis.

CNS and respiratory depression can develop rapidly, creating substantial aspiration risk.

Current FDA labeling explicitly advises against induced vomiting.

Activated Charcoal

Modern labeling recommends considering activated charcoal only in selected patients with:

• Large overdose
• Early presentation
• No significant CNS depression
• Ability to protect the airway

A typical single dose in poisoning practice is approximately:

1 g/kg

when clinically appropriate.

Important

Do not administer charcoal to a somnolent patient with an unprotected airway.

Gastric Lavage

The older chapter recommends gastric lavage routinely after a large ingestion within 1 hour.

Current 2026 FDA labeling instead emphasizes supportive treatment and selected activated charcoal and no longer recommends routine gastric lavage in its overdose management section.

Therefore:

Routine gastric lavage should not be performed.

It would only rarely be considered in an exceptionally large, immediately life-threatening recent ingestion after:

• Airway protection
• Toxicology consultation

Antidote

There is no established specific antidote.

Management is primarily:

• Ventilation
• Hemodynamic support
• Seizure treatment
• Treatment of coingestants

Flumazenil

This is an important modern pitfall.

One older case report described neurologic improvement after flumazenil in a severe carisoprodol/meprobamate intoxication.

However:

Flumazenil is not recommended routinely for carisoprodol poisoning.

Reasons include:

• Carisoprodol does not behave simply like a benzodiazepine
• Evidence consists largely of isolated case experience
• Many overdoses involve mixed drugs
• Chronic sedative users may be dependent
• Flumazenil can precipitate seizures or withdrawal

The 2025 UK expert review specifically notes that flumazenil is not recommended by the UK National Poisons Information Service for acute carisoprodol or meprobamate poisoning.

Therefore:

Do not use flumazenil as routine reversal therapy.

Hypotension

Treat initially with:

• Isotonic crystalloid if clinically fluid responsive

Avoid unnecessary large fluid volumes, particularly if prolonged severe meprobamate toxicity is suspected.

If hypotension persists despite appropriate volume:

Use a vasopressor—norepinephrine is generally an appropriate contemporary first-line choice.

The old routine preference for dopamine and Trendelenburg positioning is outdated.

Seizures

First-line:

Benzodiazepines

Examples:

• Lorazepam
• Midazolam
• Diazepam

Current carisoprodol labeling recommends IV benzodiazepines for seizures and phenobarbital when recurrent seizures persist.

For refractory status epilepticus:

• Phenobarbital
• Propofol in an intubated patient

may be appropriate.

Phenytoin is generally not preferred as routine treatment for diffuse toxin-induced seizures.

Serotonin Syndrome

If a convincing serotonergic syndrome develops:

• Stop serotonergic agents
• Benzodiazepine sedation
• External cooling for significant hyperthermia
• IV fluids as appropriate

Severe hyperthermia requires aggressive control.

Because most suspected cases involve multidrug exposures, actively search for another serotonergic agent.

Enhanced Elimination

Forced Diuresis

The older literature sometimes lists forced diuresis.

Routine forced diuresis should not be used.

It provides uncertain benefit and can cause:

• Volume overload
• Electrolyte disturbances

Hemodialysis

Carisoprodol itself is technically dialyzable, and current FDA labeling acknowledges that both hemodialysis and peritoneal dialysis can remove carisoprodol.

Meprobamate has also historically been removed by hemodialysis in severe poisoning.

However:

Hemodialysis is not routine treatment for ordinary carisoprodol overdose.

Most patients improve with:

• Airway support
• Ventilation
• Hemodynamic care
• Time

Consider extracorporeal therapy only in unusual, severe situations such as:

• Persistent profound coma/respiratory failure
• Severe refractory hypotension
• Progressive deterioration despite intensive supportive treatment
• Marked meprobamate accumulation
• Severe toxicity with impaired renal elimination

This decision should involve:

• Medical toxicology/poison center
• Nephrology

There are no modern standardized EXTRIP-type indications for carisoprodol.

Monitoring

Symptomatic patients require:

• Continuous pulse oximetry
• Frequent respiratory assessment
• Continuous ECG in significant poisoning
• Blood pressure monitoring
• Serial neurologic examinations

Consider:

• Capnography

because hypoventilation may develop before hypoxemia becomes obvious.

Observation

Carisoprodol itself has a relatively short half-life, but the active metabolite:

Meprobamate lasts considerably longer.

Therefore, a rigid historical:

“6 hours = safe discharge”

should not be applied to every exposure.

Observation duration should account for:

• Dose
• Clinical symptoms
• Coingestants
• Chronic use
• Renal/hepatic dysfunction
• Recurrent sedation

Admission

Hospital admission is appropriate for:

• Significant CNS depression
• Ataxia preventing safe ambulation
• Recurrent vomiting with sedation
• Hypotension
• Seizures
• Abnormal movements with substantial toxicity
• Respiratory depression
• Significant intentional overdose
• Major coingestants

ICU care is appropriate for:

• Intubation/mechanical ventilation
• Coma
• Recurrent seizures
• Shock
• Severe mixed overdose

Discharge

Discharge should require:

• Normal or baseline mental status
• Normal ventilation
• Stable vital signs
• Safe ambulation
• No recurrent sedation
• No clinically important coingestant toxicity

Intentional overdose requires appropriate psychiatric/safety assessment.

A patient should not be discharged simply because initial carisoprodol effects improved if significant:

• Opioid
• Benzodiazepine
• Salicylate
• Meprobamate

toxicity remains possible.

Dependence and Withdrawal

Long-term carisoprodol therapy should be avoided.

Current labeling specifically limits therapeutic use to:

2–3 weeks

partly because abuse, dependence, and withdrawal have been documented.

A patient chronically taking large doses may require an individualized taper rather than abrupt discontinuation.

Pregnancy

The historical FDA Pregnancy Category C classification is obsolete.

Current labeling states that decades of available human data have not identified a consistent drug-associated increase in major birth defects, miscarriage, or other adverse pregnancy outcomes from carisoprodol, and available meprobamate data likewise do not show a consistent major-malformation pattern.

This does not make overdose benign.

In maternal poisoning:

Maternal airway, ventilation, and circulation remain the priorities.

Breastfeeding

Carisoprodol and meprobamate can enter breast milk.

A breastfed infant should be monitored for:

Sedation

Current labeling reports at least one infant sedation case.

Prognosis

Most isolated mild-to-moderate overdoses recover completely with good supportive care.

Poor outcomes are usually related to:

• Respiratory arrest
• Aspiration
• Prolonged hypoxia
• Severe hypotension
• Seizures
• Multiple CNS depressants

Fatal poisoning can occur, including with carisoprodol alone, but the risk is markedly greater with:

• Opioids
• Benzodiazepines
• Alcohol

Important Pitfalls

1. Thinking carisoprodol is merely a “muscle relaxant”

Clinically it behaves as a:

Centrally acting sedative drug with an active sedative-hypnotic metabolite.

2. Ignoring meprobamate

Carisoprodol half-life:

~2 h

Meprobamate:

~10 h

Therefore, toxicity may persist after the parent drug has substantially declined.

3. Missing opioid coingestion

Carisoprodol is frequently encountered with other CNS depressants.

Respiratory depression should prompt consideration of:

Opioid coexposure → naloxone when appropriate

while simultaneously supporting ventilation.

4. Assuming all toxicity is simple sedation

High-dose carisoprodol may instead produce:

• Myoclonus
• Tremor
• Agitation
• Abnormal movements
• Delirium
• Serotonergic features

5. Giving flumazenil routinely

Despite an isolated successful case report:

Flumazenil is not an established carisoprodol antidote and is not routinely recommended.

6. Performing routine gastric lavage

Current labeling favors:

Selected activated charcoal in an early large overdose with an intact airway

rather than routine gastric lavage.

7. Giving charcoal to a sedated patient

Carisoprodol can rapidly impair airway reflexes.

Airway protection takes priority over decontamination.

8. Forgetting combination formulations

A preparation may contain:

• Aspirin
• Codeine

An unexplained:

• Acidosis
• Tinnitus
• Tachypnea

should prompt evaluation for salicylate toxicity.

Respiratory depression/miosis should prompt evaluation for opioid toxicity.

9. Missing dependence and withdrawal

Abrupt cessation after prolonged high-dose use can cause:

Tremor + insomnia + hallucinations + psychosis

and should not be mistaken automatically for a new psychiatric disorder.

10. Assuming dialysis is standard treatment

Carisoprodol is technically dialyzable, but:

Most overdoses are managed with supportive care.

Extracorporeal removal is reserved for exceptional severe cases after specialist consultation.

High-Yield Toxicology Pearls

Carisoprodol overdose = sedative toxicity with a long-acting meprobamate metabolite

Think:

Ataxia + drowsiness → coma + respiratory depression ± hypotension

but remember that the parent drug can also produce:

Agitation + tremor/myoclonus + abnormal movements

Key points:

• Carisoprodol is a centrally acting muscle relaxant
• U.S. Schedule IV
• Current adult dose: 250–350 mg TID + bedtime
• Therapeutic use should be limited to 2–3 weeks
• Safety/efficacy are not established below age 16
• Metabolism:
• 
  
• CYP2C19 → meprobamate
• Half-life:
• 
  
• Carisoprodol ~2 h
• Meprobamate ~10 h
• Poor CYP2C19 metabolizers can have substantially increased parent-drug exposure
• Major toxicity:
• 
  
• CNS depression
• Respiratory depression
• Coma
• Hypotension
• Seizures
• Carisoprodol itself may cause:
• 
  
• Agitation
• Myoclonus
• Rigidity/dystonia
• Serotonergic features
• Major overdose danger:
• 
  
• Opioids
• Benzodiazepines
• Alcohol
• Main treatment:
• 
  
• Airway + ventilation + supportive care
• Naloxone treats an opioid coingestion, not carisoprodol itself
• Do not induce vomiting
• Activated charcoal only for selected early, large exposures with an intact/protected airway
• Routine gastric lavage is obsolete
• Seizures → benzodiazepines
• Recurrent seizures → phenobarbital
• No specific antidote
• Do not routinely use flumazenil
• Persistent hypotension → fluids when appropriate + norepinephrine
• Forced diuresis is not recommended
• Carisoprodol/meprobamate are dialyzable, but hemodialysis is not routine
• Chronic use can cause dependence and significant withdrawal
• Withdrawal may cause:
• 
  
• Insomnia
• Tremor
• Muscle twitching
• Hallucinations
• Psychosis
• Most patients recover completely if respiratory failure and hypoxia are prevented